BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 28714964)

  • 1. Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma.
    Rodriguez-Blanco J; Pednekar L; Penas C; Li B; Martin V; Long J; Lee E; Weiss WA; Rodriguez C; Mehrdad N; Nguyen DM; Ayad NG; Rai P; Capobianco AJ; Robbins DJ
    Oncogene; 2017 Nov; 36(45):6306-6314. PubMed ID: 28714964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
    Li Y; Song Q; Day BW
    Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
    Singh AR; Joshi S; Zulcic M; Alcaraz M; Garlich JR; Morales GA; Cho YJ; Bao L; Levy ML; Newbury R; Malicki D; Messer K; Crawford J; Durden DL
    PLoS One; 2016; 11(3):e0150836. PubMed ID: 26938241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 Function Is Compromised by Inhibitor 2 of Phosphatase 2A in Sonic Hedgehog Medulloblastoma.
    Wei Y; Maximov V; Morrissy SA; Taylor MD; Pallas DC; Kenney AM
    Mol Cancer Res; 2019 Jan; 17(1):186-198. PubMed ID: 30224541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noncanonical activation of GLI signaling in SOX2
    Swiderska-Syn M; Mir-Pedrol J; Oles A; Schleuger O; Salvador AD; Greiner SM; Seward C; Yang F; Babcock BR; Shen C; Wynn DT; Sanchez-Mejias A; Gershon TR; Martin V; McCrea HJ; Lindsey KG; Krieg C; Rodriguez-Blanco J
    Sci Adv; 2022 Jul; 8(29):eabj9138. PubMed ID: 35857834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.
    Faria CC; Golbourn BJ; Dubuc AM; Remke M; Diaz RJ; Agnihotri S; Luck A; Sabha N; Olsen S; Wu X; Garzia L; Ramaswamy V; Mack SC; Wang X; Leadley M; Reynaud D; Ermini L; Post M; Northcott PA; Pfister SM; Croul SE; Kool M; Korshunov A; Smith CA; Taylor MD; Rutka JT
    Cancer Res; 2015 Jan; 75(1):134-46. PubMed ID: 25391241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraventricular SHH inhibition proves efficient in SHH medulloblastoma mouse model and prevents systemic side effects.
    Kresbach C; Holst L; Schoof M; Leven T; Göbel C; Neyazi S; Tischendorf J; Loose C; Wrzeszcz A; Yorgan T; Rutkowski S; Schüller U
    Neuro Oncol; 2024 Apr; 26(4):609-622. PubMed ID: 37767814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
    Pak E; MacKenzie EL; Zhao X; Pazyra-Murphy MF; Park PMC; Wu L; Shaw DL; Addleson EC; Cayer SS; Lopez BG; Agar NYR; Rubin LL; Qi J; Merk DJ; Segal RA
    Neuro Oncol; 2019 Sep; 21(9):1150-1163. PubMed ID: 31111916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A CK1α Activator Penetrates the Brain and Shows Efficacy Against Drug-resistant Metastatic Medulloblastoma.
    Rodriguez-Blanco J; Li B; Long J; Shen C; Yang F; Orton D; Collins S; Kasahara N; Ayad NG; McCrea HJ; Roussel MF; Weiss WA; Capobianco AJ; Robbins DJ
    Clin Cancer Res; 2019 Feb; 25(4):1379-1388. PubMed ID: 30487124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SHH inhibitors for the treatment of medulloblastoma.
    Samkari A; White J; Packer R
    Expert Rev Neurother; 2015; 15(7):763-70. PubMed ID: 26027634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sox2 requirement in sonic hedgehog-associated medulloblastoma.
    Ahlfeld J; Favaro R; Pagella P; Kretzschmar HA; Nicolis S; Schüller U
    Cancer Res; 2013 Jun; 73(12):3796-807. PubMed ID: 23596255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quiescent sox2(+) cells drive hierarchical growth and relapse in sonic hedgehog subgroup medulloblastoma.
    Vanner RJ; Remke M; Gallo M; Selvadurai HJ; Coutinho F; Lee L; Kushida M; Head R; Morrissy S; Zhu X; Aviv T; Voisin V; Clarke ID; Li Y; Mungall AJ; Moore RA; Ma Y; Jones SJ; Marra MA; Malkin D; Northcott PA; Kool M; Pfister SM; Bader G; Hochedlinger K; Korshunov A; Taylor MD; Dirks PB
    Cancer Cell; 2014 Jul; 26(1):33-47. PubMed ID: 24954133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma.
    Purzner T; Purzner J; Buckstaff T; Cozza G; Gholamin S; Rusert JM; Hartl TA; Sanders J; Conley N; Ge X; Langan M; Ramaswamy V; Ellis L; Litzenburger U; Bolin S; Theruvath J; Nitta R; Qi L; Li XN; Li G; Taylor MD; Wechsler-Reya RJ; Pinna LA; Cho YJ; Fuller MT; Elias JE; Scott MP
    Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
    Zhang ZY; Xu J; Ren Y; Li KK; Ng HK; Mao Y; Zhong P; Yao Y; Zhou LF
    PLoS One; 2014; 9(6):e99490. PubMed ID: 24932704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WIP1 enhances tumor formation in a sonic hedgehog-dependent model of medulloblastoma.
    Doucette TA; Yang Y; Pedone C; Kim JY; Dubuc A; Northcott PD; Taylor MD; Fults DW; Rao G
    Neurosurgery; 2012 Apr; 70(4):1003-10; discussion 1010. PubMed ID: 22037313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hedgehog pathway permissive conditions allow generation of immortal cell lines from granule cells derived from cancerous and non-cancerous cerebellum.
    Heil C
    Open Biol; 2019 Jan; 9(1):180145. PubMed ID: 30958113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.
    Robinson GW; Orr BA; Wu G; Gururangan S; Lin T; Qaddoumi I; Packer RJ; Goldman S; Prados MD; Desjardins A; Chintagumpala M; Takebe N; Kaste SC; Rusch M; Allen SJ; Onar-Thomas A; Stewart CF; Fouladi M; Boyett JM; Gilbertson RJ; Curran T; Ellison DW; Gajjar A
    J Clin Oncol; 2015 Aug; 33(24):2646-54. PubMed ID: 26169613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy.
    Ocasio JK; Babcock B; Malawsky D; Weir SJ; Loo L; Simon JM; Zylka MJ; Hwang D; Dismuke T; Sokolsky M; Rosen EP; Vibhakar R; Zhang J; Saulnier O; Vladoiu M; El-Hamamy I; Stein LD; Taylor MD; Smith KS; Northcott PA; Colaneri A; Wilhelmsen K; Gershon TR
    Nat Commun; 2019 Dec; 10(1):5829. PubMed ID: 31863004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neogenin1 is a Sonic Hedgehog target in medulloblastoma and is necessary for cell cycle progression.
    Milla LA; Arros A; Espinoza N; Remke M; Kool M; Taylor MD; Pfister SM; Wainwright BJ; Palma V
    Int J Cancer; 2014 Jan; 134(1):21-31. PubMed ID: 23775842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. β-Catenin-Gli1 interaction regulates proliferation and tumor growth in medulloblastoma.
    Zinke J; Schneider FT; Harter PN; Thom S; Ziegler N; Toftgård R; Plate KH; Liebner S
    Mol Cancer; 2015 Feb; 14(1):17. PubMed ID: 25645196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.